Ontario Teachers Pension Plan Board Grows Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Ontario Teachers Pension Plan Board lifted its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 77.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 38,366 shares of the medical equipment provider's stock after purchasing an additional 16,729 shares during the quarter. Ontario Teachers Pension Plan Board's holdings in Hologic were worth $2,766,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in HOLX. General Partner Inc. acquired a new position in Hologic in the fourth quarter valued at approximately $26,000. Venturi Wealth Management LLC increased its holdings in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 260 shares during the period. Smartleaf Asset Management LLC lifted its stake in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Finally, Smithfield Trust Co grew its stake in shares of Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on HOLX shares. Stephens reissued an "overweight" rating and set a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and lowered their price objective for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Evercore ISI dropped their price objective on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a report on Thursday, February 6th. Finally, Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Hologic presently has an average rating of "Hold" and a consensus price target of $84.62.

Hologic Stock Up 1.9 %

HOLX stock traded up $1.06 during trading on Friday, hitting $57.56. 6,818,925 shares of the company's stock were exchanged, compared to its average volume of 1,953,652. The stock has a market capitalization of $12.92 billion, a price-to-earnings ratio of 18.16, a PEG ratio of 2.14 and a beta of 0.82. Hologic, Inc. has a 52-week low of $55.89 and a 52-week high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The business has a 50-day moving average price of $61.58 and a two-hundred day moving average price of $70.76.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.